1.Ferlay J. et al. Cancer statistics for the year 2020: An overview // Int J Cancer. 2021. Vol. 149, No 4.1-122.Siegel R.L. et al. Cancer statistics, 2023 // CA Cancer J Clin. 2023. Vol. 73, No 1. 17-483.Karpiński T.M., Adamczak A. Anticancer activity of bacterial proteins and peptides // Pharmaceutics. 2018. Vol. 10, No 2.2-26https://www.iqvia.com/insights/the-iqvia-institute/reports-and publications/reports/global-oncology4.D’Aiello A., Miao E., Cheng H. Advances in the Management of Central Nervous System Metastases in Non-Small Cell Lung Cancer // Cancers. 2023. Vol.15,No3.4-165.Blaukat A. Tyrosine Kinase Inhibitors // Encyclopedia of Molecular Pharmacology / ed. Offermanns Stefan and Rosenthal W. Berlin, Heidelberg: Springer Berlin Heidelberg, 2008. P. 1253–1257.6.Narayan V. et al. Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With VEGFR TKIs // JNCCN Journal of the National Comprehensive Cancer Network. 2023. Vol. 21, No 10. 150-1757.Zhong L. et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives // Signal Transduction and Targeted Therapy. 2021.Vol. 6, No 1. 11-488.Shimada A. Hematological malignancies and molecular targeting therapy // European Journal of Pharmacology. 2019. Vol. 862. 124-1389.Hartmann J. et al. Tyrosine Kinase Inhibitors –A Review on Pharmacology, Metabolism and Side Effects // Curr Drug Metab. 2009. Vol. 10, No 5. 252-27610.Morana O., Wood W., Gregory C.D. The Apoptosis Paradox in Cancer // International Journal of Molecular Sciences. 2022. Vol. 23, No 3. 48-6411.Lu L. et al. Tumor necrosis factor-αsensitizes breast cancer cells to natural products with proteasome-inhibitory activity leadingto apoptosis // PLoS One. 2014. Vol. 9, No 11. 23-3812.Han Z. et al. Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review // EJNMMI Research. 2017. Vol. 7.WO 2005/075454A 13.Zhang Z. et al. CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials // Pharmaceutics. 2022. Vol. 14, No 1. 178-19914.Li H. et al. Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo // Journal of Experimental and Clinical Cancer Research. 2016. Vol. 35, No 1. 52-6615.Chen X.J. et al. Effect of Etoposide on Elimination of Chronic Myeloid Leukemia Stem Cells by Imatinib in Vivo // Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021. Vol. 29, No 2.15-2916.Yevropeyskaya konvensiya po zashite pozvonochnix jivotnix, ispolzuyemix v eksperimentalnix i drugix nauchnix selyax // ETS No 123. 82-981986 –Strasburg (Konvensiya)17.Mironov A.N. Metodicheskiye rekomendatsii po izucheniyu obshetoksicheskogo deystviya lekarstvennix, “Rukovodstvo po provedeniyu doklinicheskix issledovaniy lekarstvennix sredstv” I chast, 2012, Mironov A.N., Bunyatyan N.D. i dr //, 2012 g. S. 15-17.18.Metodi ispitaniye po vozdeystviyu ximicheskoy produksii na organizm cheloveka. Ostraya peroralnaya toksichnost-metod opredeleniye klassa ostroy toksichnosti. (OECD, Test No423: 2001, IDT) Minsk 2013 36-61 19.Karolewicz B. et al. Molecular mobility and stability studies of amorphous imatinib mesylate // Pharmaceutics. 2019. Vol. 11, No 7. 12-2820.Al-Hadiya B.M.H., Bakheit A.H.H., Abd-Elgalil A.A. Chapter Six –Imatinib Mesylate // Profiles of Drug Substances, Excipients and Related Methodology. 2014. Vol. 39. 124-135